反应性氧物种调制在当前的抗癌疗法的风景
Jiaqi Li1, Justin Yi Shen Lim2, Jie Qing Eu3
1Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Antioxidants & redox signaling
|March 6, 2024
概括
反应性氧物种 (ROS) 在癌症中起着双重作用,促进生长或死亡. 通过亲氧化剂策略向ROS提供了有前途的治疗途径,尽管优化治疗方法和识别生物标志物的挑战仍然存在.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 活性氧物种 (ROS) 对于细胞的氧化还原平衡至关重要,调节正常的细胞生长.
- 癌细胞表现出改变的ROS水平,导致氧化应激,基因组不稳定性和异常信号传递.
- 在癌症进展中,ROS,瘤信号,瘤微环境和DNA损伤反应 (DDR) 之间的相互作用至关重要.
研究的目的:
- 审查ROS在癌症中的多方面的作用.
- 探索ROS调制作为治疗癌症的治疗策略.
- 讨论目前和新兴的治疗方式,以向癌症治疗中的ROS.
主要方法:
- 文献综述侧重于ROS,瘤信号传递,瘤微环境和DDR通路之间的相互作用.
- 在癌症治疗中分析"抗氧化剂"和"亲氧化剂"方法.
- 检查各种治疗方式,包括直接的ROS诱导剂,化疗,向疗法,DDR疗法,放射疗法和免疫疗法.
- 讨论像纳米敏化剂这样的新型传递系统.
主要成果:
- 虽然抗氧化剂方法的常规使用证据有限,但亲氧化剂策略通过利用癌症特异性漏洞显示出有前途.
- 包括化疗,向治疗,放射治疗和免疫治疗在内的治疗方式可以诱导氧化应激.
- 像纳米敏化剂这样的新兴技术正在开发中,以提高放射治疗的疗效.
结论:
- 调节ROS为增强现有的抗癌治疗和开发新的治疗机会提供了一个有希望的策略.
- 针对癌症脆弱性的亲氧化剂方法显示出克服对传统疗法的耐药性的潜力.
- 需要进一步的研究来完善基于ROS的治疗策略,优化药物组合,并确定患者选择的预测生物标志物.
更多相关视频
10:05Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
Published on: May 8, 2020
1.9K
14:25Quantification of Reactive Oxygen Species Using 2′,7′-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in Müller Glial Cells
Published on: May 13, 2022
6.7K
相关概念视频
Electron Transport Chain: Complex I and II
13.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
